ISOLUTE® HYDRO DME+ columns and plates provide extremely efficient removal of matrix components and hydrolysis enzyme from urine and other biological fluid samples, using a simple pass through workflow.
Part No. | Description | Pack Size | List Price | |
---|---|---|---|---|
970-0400-PZ01 | ISOLUTE® HYDRO DME+ 400 mg Plate | 1 | 183 USD | Add to quote/cart |
970-0040-BZ | ISOLUTE® HYDRO DME+ 400 mg/3 mL Columns | 50 | 95 USD | Add to quote/cart |
Ideal for drugs of abuse and pain management applications, the inclusion of Biotage® HYDRO frit technology means that urine samples can be hydrolyzed in-situ in the column, eliminating the need for post hydrolysis sample transfer steps.
Dual Mode Extraction (DME) has been developed by Biotage to provide more effective removal of matrix components from urine (and other biological fluid samples) using a combination of liquid partitioning and scavenging modes. This novel extraction technology quickly and easily removes urinary components such as pigments, salts, urea, creatinine and residual hydrolysis enzyme, leaving the sample visually clear and reducing matrix effects. Cleaner extracts mean you can inject 2 x as many samples as D&S, without loss of sensitivity.
In addition to maintaining instrument performance, cleaner extracts mean lower LOQs than with D&S.
Because the HYDRO frit technology holds all of the sample above the sorbent bed during the elevated temperature incubation process, hydrolysis efficiency when using ISOLUTE® HYDRO DME+ is equivalent to off-line hydrolysis under the same conditions. Existing hydrolysis procedures can easily be transferred to ISOLUTE® HYDRO DME+.
Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers’ workflows and improving their outcomes. Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT).
Copyright © 2024 Biotage